智擎 (4162.TWO)

95.50 +0.20 (+0.21%) 收市：01:30PM CST

智擎

10 Minsheng East Road
11th Floor Sec. 3
Taipei 104
Taiwan
886 2 2515 8228
https://www.pharmaengine.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Hong-Ren Wang Ph.D.	President & CEO	無	無	無
Jose Hsieh	Senior Manager of Accounting	無	無	無
Mr. Chi-Hsing Chang	Vice President of Corporate Development	4.02M	無	無
Melody Lin	Director of Human Resources	無	無	無

截止 2020年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

公司管治

截至 無 止，智擎 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。